No Detail Found!

Insulin Resistance and the Prognosis in Di use Large B-cell Lymphoma

Author(s)
Wei-Ling Zhou Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Xiao-Juan Hou Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Li-Hong Liu Department of Hematology, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Qian Gao Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Lei Feng Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Yuan Wang Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital),Shijiazhuang, Hebei,China
Abstract
Objective: To investigate whether insulin resistance (IR) a ects the prognosis in patients with di use large B-cell lymphoma (DLBCL). Place and Duration of the Study: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, from September 2017 to December 2021. Methodology: This study retrospectively analysed 324 patients with DLBCL who were divided into a non-IR group (251 cases) and IR group (73 cases) according to IR. The authors collected clinical data of the study population and calculated the overall survival (OS) of patients through inpatient case data or follow-up. The Cox regression method was used to assess the prognostic factors of the patients. The Kaplan Meier method was used for drawing the survival curve of IR on OS of the DLBCL patients. Results: The IR group had older age, higher international prognostic index (IPI), later stage, and higher insulin levels. The veyear OS rate was 46% in the IR group and 66% in the non-IR group. Compared with the non-IR group, the IR group showed a poor prognosis (OS: adjusted HR 1.23, 95% CI: 1.02 1.41, p = 0.031). Conclusion: IR was one of the factors leading to poor prognosis in patients with DLBCL, and attention should be paid to this risk factor.
Publication Details
Page(s) 411-415
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Insulin resistance, prognosis, Overall survival, Di use large B-cell lymphoma
0

Citations

0

Downloads

75

Views